Provided by Tiger Trade Technology Pte. Ltd.

Weight Loss Drugs

1,284.13
-24.4164-1.87%
Number of Gainers:- -
Number of Losers:7
Number of Flat:- -
PE:- -
High:1,313.31
Open:1,310.05
Low:1,283.00
Close:1,308.55
Volume:55.14M
Turnover:4.71B
Market Cap:1.34T
Float Cap:1.29T

Loading ...

Structure Therapeutics Obesity Trial Success Puts Valuation Gap In Focus

Simply Wall St.
·
10 hours ago

Income Investing: 6 Stocks Worth Buying That Yield More Than 5% -- Barron's

Dow Jones
·
12 hours ago

Novavax Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
16 hours ago

Catalyst Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
16 hours ago

Biogen Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
16 hours ago

Bristol Myers Squibb Co. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
17 hours ago

Pfizer Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
17 hours ago

Gilead Sciences Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
17 hours ago

Amgen Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
17 hours ago

Mixed options sentiment in Novo Nordisk with shares down 1.09%

TIPRANKS
·
18 hours ago

Eli Lilly Allowed to Pursue Claims in Tirzepatide Marketing Lawsuit Against Fella Health

MT Newswires Live
·
20 hours ago

Novo Nordisk A/S Stock Falls Friday, Outperforms Market

Dow Jones
·
20 hours ago

Option traders moderately bearish in Pfizer with shares down 0.67%

TIPRANKS
·
Yesterday

Eli Lilly and Co Stock (LLY) Moved Down by 3.05% on Mar 27: Drivers Behind the Movement

TradingKey
·
Yesterday

Eli Lilly Says Long-Term Data Shows Eczema Treatment Provides Up to Four Years of Disease Control

MT Newswires Live
·
Yesterday

Eli Lilly announces new long term data from study of EBGLYSS

TIPRANKS
·
Yesterday

Eli Lilly ADlong Phase 3b trial EASI-75 rate climbs to 94%; EASI-90 rate rises to 75%

Reuters
·
Yesterday

BRIEF-Lilly's Ebglyss (Lebrikizumab-Lbkz) Delivered Up To Four Years Of Durable Disease Control For Patients With Moderate-To-Severe Atopic Dermatitis

Reuters
·
Yesterday

Lilly's Ebglyss (Lebrikizumab-Lbkz) Delivered up to Four Years of Durable Disease Control for Patients With Moderate-to-Severe Atopic Dermatitis

THOMSON REUTERS
·
Yesterday

Eli Lilly - Ebglyss Delivers Four Years of Durable Disease Control for Atopic Dermatitis

THOMSON REUTERS
·
Yesterday